Teva Resolves $450M Lawsuits Over Copaxone Kickbacks and Generic Price-Fixing Allegations

Teva Pharmaceuticals has agreed to pay $450 million to resolve allegations of violating the Anti-Kickback Statute and the False Claims Act, according to the U.S. Department of Justice. This settlement includes $425 million addressing claims that Teva used assistance foundations to cover copays for their multiple sclerosis drug, Copaxone, while its price significantly increased from 2006 to 2017. An additional $25 million settles accusations of price-fixing with other generic drugmakers on medications such as pravastatin, clotrimazole, and tobramycin. While Teva has not admitted wrongdoing, the company plans to pay the settlement over six years, emphasizing that the donations benefited MS patients[1][2].